Home » Newsletters » BioWorld Science

BioWorld Science

July 16, 2002

View Archived Issues

Abiogen and Philogen collaborate on hepatitis C and tetanus vaccines

Altocor approved for hypercholesterolemia, deemed approvable for CHD

AGY raises funds to advance CNS drug programs

Bay-58-2667, a novel sGC activator with potential in cardiovascular diseases

Merger of Pfizer and Pharmacia will create industry giant

S1P3 antagonists identified at U. of Virginia

New hypolipidemic agent acts through PPARalpha receptor activation

Invisible Condom generally well tolerated in phase I clinical study

Potent HIV integrase inhibitor successfully completes preclinical testing

Preclinical data suggest utility of alpha2-adrenoceptor antagonist in PD

Novel guanylate cyclase activators in the Bayer pipeline

Cell adhesion inhibitors identified by Kowa team

Tularik and Roche present novel IKK modulators

Merck patents alpha5-selective GABA-A modulators for cognition disorders

New CB2 agonists and their use in autoimmune diseases, etc.

Acarbose delays development of type 2 diabetes

Sanofi-Synthelabo claims new PARP inhibitors in recent patent

Dietary intake of vitamin C and E may lower the risk of Alzheimer's disease

Capecitabine + docetaxel improves survival in advanced breast cancer

Serine protease inhibitors with anticoagulant activity described by Pharmacia

Eupolauridine targets fungal topoisomerase II, not topoisomerase I

Hematopoietic stem cell gene therapy combined with nonmyeloblative conditioning in ADA-SCID

Atridox to be studied in chronic periodontitis/heart disease trial

Alimta expanded access program cleared for malignant pleural mesothelioma

GenVec and DirectGene collaborate to develop targeted cancer therapies

Aromasin approved in Japan for postmenopausal breast cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan. 13, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for January 13, 2025
Caplyta star shines as J&J takes Intra-Cellular in $14.6B deal
BioWorld
The J.P. Morgan (JPM) Healthcare Conference in San Francisco kicked off with a resounding bang as Johnson & Johnson (J&J) disclosed plans to acquire...
Proteomics study explores how protein changes influence disease
BioWorld Science
Fourteen global pharma companies are getting together to conduct the largest proteomics study to date, analyzing 600,000 blood samples held in the UK Biobank to...
Type 1 diabetes breakthrough? Sana threads key ‘islet,’ SC-451 to advance
BioWorld
Sana Biotechnology Inc. CEO Steve Harr said “cool and transformative science” led to his firm’s latest strides in type 1 diabetes, and the “very generalizable...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.